Inhibition of experimental proliferative vitreoretinopathy with protein kinase C inhibitor (chelerythrine chloride) and melatonin

Ophthalmologica

Volumn 220, Issue 1, 2005, Pages 17-22

  Er, Hamdi ^a   Turkoz, Yusuf ^a   Mizrak, Bülent ^a   Parlakpinar, Hakan ^a  

^a INONU UNIVERSITY   (Turkey)

Author keywords

Chelerythrine chloride; Melatonin; Proliferative vitreoretinopathy; Protein kinase C inhibitor

Indexed keywords

CHELERYTHRINE; MELATONIN; PROTEIN KINASE C INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; EYE; FEMALE; FOLLOW UP; MALE; NONHUMAN; OPHTHALMOSCOPY; RABBIT; VITREORETINOPATHY;

ALKALOIDS; ANIMALS; BENZOPHENANTHRIDINES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; FREE RADICAL SCAVENGERS; INJECTIONS; MALE; MELATONIN; PHENANTHRIDINES; PROTEIN KINASE C; RABBITS; TREATMENT OUTCOME; VITREORETINOPATHY, PROLIFERATIVE; VITREOUS BODY;

EID: 29244482228     PISSN: 00303755     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089270     Document Type: Article

References (28)

1. Kon CH, Occleston NL, Aylward GW, Khaw PT: Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study. Invest Ophthalmol Vis Sci 1999;40:705-712.
2. Van Horn DL, Aaberg TM, Machemer R: Glial cell proliferation in human retinal detachment with massive periretinal proliferation. Am J Ophthalmol 1977;84:383-393.
3. Asaria RH, Kon CH, Bunce C, et al: Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized, double-blind controlled clinical trial. Ophthalmology 2001;108:1179-1183.
4. Daniels SA, Coonley KG, Yoshizumi MO: Taxol treatment of experimental proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol 1990;228:513-516.
5. Frank RN: Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors. Am J Ophthalmol 2002;133:693-698.
6. Moriarty P, Dickson AJ, Erichsen JT, Boulton M: Protein kinase C isoenzyme expression in retinal cells. Ophthalmic Res 2000;32:57-60.
7. Murray MA, Heistad DD, Mayhan WG: Role of protein kinase C in bradykinin-induced increases in microvascular permeability. Circ Res 1991;68:1340-1348.
8. Cuzzocrea S, Zingarelli B, Gilad E, Hake P, Salzman AL, Szabo C: Protective effect of melatonin in carrageenan-induced models of local inflammation: Relationship to its inhibitory effect on nitric oxide production and its peroxynitrite scavenging activity. J Pineal Res 1997;23:106-116.
9. Crespo E, Macias M, Pozo D, et al: Melatonin inhibits expression of the inducible NO synthase II in liver and lung and prevents endotoxemia in lipopolysaccharide-induced multiple organ dysfunction syndrome in rats. FASEB J 1999;13:1537-1546.
10. Yu HS, Hernandez V, Haywood M, Wong CG: Melatonin inhibits the proliferation of retinal pigment epithelial (RPE) cells in vitro. In Vitro Cell Dev Biol Anim 1993;29:415-418.
11. The Retina Society Terminology Committee: The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology 1983;90:121-125.
12. Ohkawa H, Ohishi N, Yagi K: Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351-358.
13. Ellman GL: Tissue sulfhydryl groups. Arch Biochem Biophys 1959;82:70-77.
14. Elner SG, Elner VM, Jaffe GJ, Stuart A, Kunkel SL, Strieter RM: Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Curr Eye Res 1995;14:1045-1053.
15. Mandai M, Yoshimura Y, Yoshida M, Iwaki M, Honda Y: The role of nitric oxide synthase in endotoxin-induced uveitis: effects of NG-nitro-L-arginine. Invest Ophthalmol Vis Sci 1994;35:3673-3679.
16. Mandai M, Mittag TW, Kogishi J, et al: Role of nitric oxide synthase isozymes in endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 1996;37:826-832.
17. Dempsey EC, Newton AC, Mochyl-Rosen D, et al: Protein kinase C isozymes and regulation of diverse cell responses. Am J Physiol Lung Cell Mol Physiol 2000;279:429-438.
18. Ueda Y, Steinberg RH: Voltage-operated calcium channels in fresh and cultured rat retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 1993;34:3408-3418.
19. Mergler S, Steinhausen K, Wiederholt M, Strauss O: Altered regulation of L-type channels by protein kinase C and protein tyrosine kinases as a pathophysiologic effect in retinal degeneration. FASEB J 1998;12:1125-1134.
20. Ramesh GT, Jadhav AL: Levels of protein kinase C and nitric oxide synthase activity in rats exposed to subchronic low level lead. Mol Cell Biochem 2001;223:27-33.
21. Shizukuda Y, Tang SQ, Yokota R, Ware JA: Vascular endothelial growth factor-induced endothelial cell migration and proliferation depend on a nitric oxide-mediated decrease in protein kinase C activity. Circ Res 1999;85:247-256.
22. Ramirez MM, Kim DD, Duran WN: Protein kinase C modulates microvascular permeability through nitric oxide synthase. Am J Physiol 1996;271:1702-1705.
23. Spyridopoulos I, Luedemann C, Chen D, Kearney M, Chen D, Murohara T, Principe N, Isner JM, Losordo DW. Divergence of angiogenic and vascular permeability signaling by VEGF: inhibition of protein kinase C suppresses VEGF-induced angiogenesis, but promotes VEGF-induced, NO-dependent vascular permeability. Arterioscler Thromb Vasc Biol 2002;22:901-906.
24. 847 phosphorylation in NG108-15 neuronal cells. J Biol Chem 2000;275:28139-28143.
25. Gilad E, Wong HR, Zingarelli B, et al: Melatonin inhibits expression of the inducible isoform of nitric oxide synthase in murine macrophages: role of inhibition of NFκB activation. FASEB J 1998;12:685-693.
26. Reiter RJ, Guerrero JM, Garcia JJ, Acuna-Castroviejo D: Reactive oxygen intermediates, molecular damage, and aging: relation to melatonin. Ann NY Acad Sci 1998;854:410-424.
27. Hegazy HM, Peyman GA, Liang C, Unal MH, Molinari LC, Kazi AA: Use of perfluorocarbon liquids, silicone oil, and 5-fluorouracil in the management of experimental PVR. Int Ophthalmol 1998-99;22:239-246.
28. Hui YN, Hu D: Prevention of experimental proliferative vitreoretinopathy with daunomycin and triamcinolone based on the time course of the disease. Graefes Arch Clin Exp Ophthalmol 1999;237:601-605.